title: Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.
abstract: OBJECTIVE
  In a previous report of HIV-infected patients with fat redistribution, we found that recombinant human growth hormone (rhGH) therapy reduced visceral adipose tissue (VAT) but increased insulin resistance, and that the addition of rosiglitazone reversed the negative effects of rhGH on insulin sensitivity. In this study, we sought to determine the effects of rhGH and rosiglitazone therapy on an array of inflammatory and fibrinolytic markers.
  
  
  METHODS
  72 patients with HIV-associated abdominal obesity and insulin resistance were randomized to treatment with rhGH, rosiglitazone, the combination of rhGH and rosiglitazone, or placebo for 12 weeks. Subjects with plasma and serum samples available at weeks 0 (n=63) and 12 (n=46-48) were assessed for adiponectin, C-reactive protein, homocysteine, interleukin-1, interleukin-6, tumor necrosis factor alpha, interferon gamma, fibrinogen, plasminogen activator inhibitor-1 antigen, and tissue plasminogen activator antigen.
  
  
  RESULTS
  Treatment with both rosiglitazone alone and the combination of rosiglitazone and rhGH for 12 weeks resulted in significant increases in adiponectin levels from baseline. Adiponectin levels did not change significantly in the rhGH arm alone . There were no significant changes in the other biomarkers among the different treatment groups.
  
  
  CONCLUSIONS
  In this study of HIV-infected patients with altered fat distribution, treatment with rosiglitazone had beneficial effects on adiponectin concentrations, an effect that was also seen with a combination of rosiglitazone and rhGH. RhGH administration alone, however, did not demonstrate any significant impact on adiponectin levels despite reductions in VAT.
authors.affiliation: a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.|e Department of Medicine , Bronx-Lebanon Hospital Center , Bronx , NY , USA.
authors.forename: Vivien
authors.initials: V
authors.lastname: Leung
authors.affiliation: b Department of Healthcare Policy and Research , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Ya-Lin
authors.initials: YL
authors.lastname: Chiu
authors.affiliation: c Department of Medicine , Mount Sinai St. Luke's-Roosevelt Hospital Center , New York , NY , USA.
authors.forename: Donald P
authors.initials: DP
authors.lastname: Kotler
authors.affiliation: c Department of Medicine , Mount Sinai St. Luke's-Roosevelt Hospital Center , New York , NY , USA.
authors.forename: Jeanine
authors.initials: J
authors.lastname: Albu
authors.affiliation: a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Yuan-Shan
authors.initials: YS
authors.lastname: Zhu
authors.affiliation: a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Kirsis
authors.initials: K
authors.lastname: Ham
authors.affiliation: c Department of Medicine , Mount Sinai St. Luke's-Roosevelt Hospital Center , New York , NY , USA.
authors.forename: Ellen S
authors.initials: ES
authors.lastname: Engelson
authors.affiliation: b Department of Healthcare Policy and Research , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Hoda
authors.initials: H
authors.lastname: Hammad
authors.affiliation: b Department of Healthcare Policy and Research , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Christos
authors.affiliation: d Department of Medicine , Columbia University College of Physicians and Surgeons , New York , NY , USA.
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Donovan
authors.affiliation: d Department of Medicine , Columbia University College of Physicians and Surgeons , New York , NY , USA.
authors.forename: Henry N
authors.initials: HN
authors.lastname: Ginsberg
authors.affiliation: a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.|b Department of Healthcare Policy and Research , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Marshall J
authors.initials: MJ
authors.lastname: Glesby
mesh_terms: D050153:Abdominal Fat / Q000187:drug effects / Q000378:metabolism*; D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000276:immunology / Q000378:metabolism; D019382:Human Growth Hormone / Q000008:administration & dosage*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000378:metabolism; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D052242:Adiponectin; D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; C508600:IL6 protein, human; D015850:Interleukin-6; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D019382:Human Growth Hormone; D002097:C-Reactive Protein
keywords: Adiponectin; HIV-1; Human growth hormone; Lipodystrophy; Rosiglitazone